Regamey Julien, Kirsch Matthias, Tozzi Piergiorgio, Barras Nicolas, Marcucci Carlo, Liaudet Lucas, Hullin Roger, Yerly Patrick
Service de cardiologie, CHUV, 1011 Lausanne.
Service de chirurgie cardiaque, CHUV, 1011 Lausanne.
Rev Med Suisse. 2018 May 23;14(608):1070-1077.
Despite the benefit of the drugs acting on neuro-humoral activation and cardiac resynchronization therapy, some patients will end in a severe refractory form of heart failure: advanced heart failure. The only therapeutic options with a positive impact on mortality and quality of life are heart transplantation and permanent left ventricular assist device (LVAD). The significant technological improvements of the past 20 years lead to a reduction of the complications associated with these devices, which now allow their use not only during the waiting period preceding heart transplantation (bridge to transplant), but also as a durable therapeutic option (destination therapy).
尽管作用于神经体液激活和心脏再同步治疗的药物有一定益处，但仍有一些患者会发展为严重难治性心力衰竭：晚期心力衰竭。对死亡率和生活质量有积极影响的唯一治疗选择是心脏移植和永久性左心室辅助装置（LVAD）。过去20年里显著的技术进步降低了与这些装置相关的并发症，现在这些装置不仅可在心脏移植前的等待期使用（过渡到移植），还可作为一种持久的治疗选择（终末期治疗）。
Zotero 插件